# Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)

> **NCT04662710** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 895 (actual)

## Conditions studied

- Advanced/Metastatic Gastroesophageal Adenocarcinoma

## Interventions

- **BIOLOGICAL:** Pembrolizumab
- **BIOLOGICAL:** Lenvatinib
- **DRUG:** Oxaliplatin
- **DRUG:** Capecitabine
- **DRUG:** Leucovorin (or Levoleucovorin)
- **DRUG:** 5-FU

## Key facts

- **NCT ID:** NCT04662710
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-30
- **Primary completion:** 2024-10-29
- **Final completion:** 2026-03-30
- **Target enrollment:** 895 (ACTUAL)
- **Last updated:** 2026-04-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04662710

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04662710, "Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04662710. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*